Wednesday, January 27, 2021 3:05:13 AM
The sooner the Albatross ILJIN is gone, the better for Aurinia and its shareholders
At least their ownership is now under 10%. Maybe an institution will buy out their interest someday. With the millions of shares they acquired for peanuts, they pretty much have free rein to jerk the price around whenever they wish.
The following is from September, 2020:
ILJIN SNT may in the future take such actions with respect to its investment in Aurinia as it deems appropriate, including, without limitation, proposals for business combinations or otherwise acquiring additional Common Shares or warrants, engaging in any hedging or similar transactions with respect to Common Shares, effecting changes in the board composition, ownership structure or operations of Aurinia, submitting shareholder proposals regarding amendments to Aurinia's articles or other policies, encouraging Aurinia to pursue one or more strategic transactions and/or otherwise changing their intention with respect to any and all matters. Any such transaction or action referred to in this paragraph would be made in compliance with all applicable laws and regulations.
https://www.newswire.ca/news-releases/iljin-snt-co-ltd-announces-filing-of-early-warning-report-related-to-aurinia-pharmaceuticals-inc--880300003.html
"If only they had used their power for good instead of evil"
At least their ownership is now under 10%. Maybe an institution will buy out their interest someday. With the millions of shares they acquired for peanuts, they pretty much have free rein to jerk the price around whenever they wish.
The following is from September, 2020:
ILJIN SNT may in the future take such actions with respect to its investment in Aurinia as it deems appropriate, including, without limitation, proposals for business combinations or otherwise acquiring additional Common Shares or warrants, engaging in any hedging or similar transactions with respect to Common Shares, effecting changes in the board composition, ownership structure or operations of Aurinia, submitting shareholder proposals regarding amendments to Aurinia's articles or other policies, encouraging Aurinia to pursue one or more strategic transactions and/or otherwise changing their intention with respect to any and all matters. Any such transaction or action referred to in this paragraph would be made in compliance with all applicable laws and regulations.
https://www.newswire.ca/news-releases/iljin-snt-co-ltd-announces-filing-of-early-warning-report-related-to-aurinia-pharmaceuticals-inc--880300003.html
"If only they had used their power for good instead of evil"
Recent AUPH News
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/13/2026 11:27:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:05:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:04:33 PM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 • Business Wire • 02/19/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:12:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 09:11:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2025 01:00:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/04/2025 11:06:12 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress • Business Wire • 11/04/2025 11:00:00 AM
- Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 • Business Wire • 11/03/2025 11:00:00 AM
- Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 • Business Wire • 10/15/2025 10:00:00 AM
